Rethinking child treatments

developing evidence-based treatments - specifically for children

News & Press

News & Press

6. November, 2020

Approval for IPO listing

Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...

Read more

News & Press

18. August, 2020

Strong profiles to the Board

The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations

Read more

News & Press

26. May, 2020

Copenhagen Science

Novel painkiller is remarkably close to market, and the team is now expanding its business development activities

Read more

News & Press

14. December, 2019

TV2 Nyhederne

En nyudviklet næsespray, er dagens store nyhed i TV2 Nyhederne - udviklet på Rigshospitalet af ledende eksperter

Read more

Facts about Children

Facts

31. August, 2020

DR.dk focus

Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...

Read more

Facts

1. May, 2020

High off-label use

Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...

Read more

Facts

1. May, 2020

Small adults?

Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details